These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 19037881

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats.
    Ko GJ, Kang YS, Han SY, Lee MH, Song HK, Han KH, Kim HK, Han JY, Cha DR.
    Nephrol Dial Transplant; 2008 Sep; 23(9):2750-60. PubMed ID: 18388116
    [Abstract] [Full Text] [Related]

  • 4. Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism.
    Fogo AB.
    Curr Opin Nephrol Hypertens; 2008 May; 17(3):282-5. PubMed ID: 18408479
    [Abstract] [Full Text] [Related]

  • 5. Peroxisome proliferator-activated receptor gamma agonists: their role as vasoprotective agents in diabetes.
    Blaschke F, Caglayan E, Hsueh WA.
    Endocrinol Metab Clin North Am; 2006 Sep; 35(3):561-74, ix. PubMed ID: 16959586
    [Abstract] [Full Text] [Related]

  • 6. Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation.
    Belvisi MG, Hele DJ, Birrell MA.
    Eur J Pharmacol; 2006 Mar 08; 533(1-3):101-9. PubMed ID: 16458290
    [Abstract] [Full Text] [Related]

  • 7. Vascular effects of PPARgamma activators - from bench to bedside.
    Marx N, Walcher D.
    Prog Lipid Res; 2007 Nov 08; 46(6):283-96. PubMed ID: 17637478
    [Abstract] [Full Text] [Related]

  • 8. Peroxisome proliferator activated receptor alpha/gamma dual agonist tesaglitazar attenuates diabetic nephropathy in db/db mice.
    Cha DR, Zhang X, Zhang Y, Wu J, Su D, Han JY, Fang X, Yu B, Breyer MD, Guan Y.
    Diabetes; 2007 Aug 08; 56(8):2036-45. PubMed ID: 17536062
    [Abstract] [Full Text] [Related]

  • 9. Diabetes and cardiovascular risk markers.
    Erdmann E.
    Curr Med Res Opin; 2005 Aug 08; 21 Suppl 1():S21-8. PubMed ID: 15811196
    [Abstract] [Full Text] [Related]

  • 10. Plasma cell membrane glycoprotein 1 (PC-1): a marker of insulin resistance in obesity, uremia and diabetes mellitus.
    Stefanović V, Antić S.
    Clin Lab; 2004 Aug 08; 50(5-6):271-8. PubMed ID: 15209435
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Peroxisome proliferator-activated receptor [gamma] agonist provides superior renal protection versus angiotensin-converting enzyme inhibition in a rat model of type 2 diabetes with obesity.
    Baylis C, Atzpodien EA, Freshour G, Engels K.
    J Pharmacol Exp Ther; 2003 Dec 08; 307(3):854-60. PubMed ID: 14560039
    [Abstract] [Full Text] [Related]

  • 13. Insulin resistance and PPAR insulin sensitizers.
    Bhatia V, Viswanathan P.
    Curr Opin Investig Drugs; 2006 Oct 08; 7(10):891-7. PubMed ID: 17086933
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. PPARgamma and atherosclerosis.
    Staels B.
    Curr Med Res Opin; 2005 Oct 08; 21 Suppl 1():S13-20. PubMed ID: 15811195
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [The role of peroxisome proliferator-activated receptor gamma in the pathogenesis of diabetes and atheromatosis].
    Gacka M, Adamiec R, Dobosz T, Szymaniec S, Bednarska-Chabowska D.
    Przegl Lek; 2004 Oct 08; 61(12):1436-9. PubMed ID: 15850344
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Peroxisome proliferator-activated receptor gamma as a novel therapeutic target in asthma.
    Park SJ, Lee YC.
    J Asthma; 2008 Oct 08; 45(1):1-8. PubMed ID: 18259989
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.